Secondary Acute Myeloid Leukemia: A Primary Challenge of Diagnosis and Treatment

Hematol Oncol Clin North Am. 2020 Apr;34(2):449-463. doi: 10.1016/j.hoc.2019.11.003. Epub 2020 Jan 7.

Abstract

Secondary acute myeloid leukemia (sAML) is a complex diagnosis that includes AML caused by either an antecedent hematologic disease (AML-AHD) or from previous treatment with chemotherapy or radiation. This disease carries a poor prognosis and is historically chemorefractory; additionally, often patients are ineligible for standard chemotherapy because of advanced age and other comorbidities. The advances of molecular diagnostics and reclassification of World Health Organization criteria have aided in the categorization of this disease. This article describes the etiology and pathophysiology of sAML, and delves into past successful treatments as well as promising new treatments.

Keywords: Acute Myeloid Leukemia Caused by an Antecedent Hematologic Disease; Acute Myeloid Leukemia with Myelodysplastic-Related Changes; Acute myeloid leukemia; Secondary acute myeloid leukemia; Therapy-related acute myeloid leukemia.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Combined Modality Therapy
  • Disease Management
  • Disease Susceptibility
  • Genetic Predisposition to Disease
  • Humans
  • Incidence
  • Leukemia, Myeloid, Acute / diagnosis*
  • Leukemia, Myeloid, Acute / etiology*
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / therapy*
  • Prognosis
  • Treatment Outcome

Substances

  • Biomarkers, Tumor